Aldoxorubicin may be safe, effective for advanced soft-tissue sarcoma

the ONA take:

Single-agent aldoxorubicin, a novel albumin-binding prodrug of doxorubicin, showed superior efficacy over doxorubicin and manageable adverse effects in patients with advanced soft-tissue sarcoma, a new study published online ahead of print in JAMA Oncology has shown.

For the international, multicenter, open-label, phase 2b study, researchers enrolled 126 patients with previously untreated locally advanced, unresectable, or metastatic soft-tissue sarcoma. Participants were randomly assigned 2:1 to receive aldoxorubicin 350 mg/m2 or doxorubicin 75 mg/m2 administered intravenously once every 3 weeks for up to six cycles.

Results showed that median progression-free survival was significantly improved with aldoxorubicin compared with doxorubicin. In addition, 6-month progression-free survival rates and tumor response rates were significantly improved with aldoxorubicin.

In regard to safety, no acute cardiotoxic effects were observed with either treatment, but left ventricular ejection fraction less than 50% occurred in 3 of 40 patients who received doxorubicin. Grade 3 or 4 neutropenia occurred more frequently in the aldoxorubicin group.

The findings suggest that further investigation of aldoxorubicin therapy in advanced soft-tissue sarcoma is warranted.

Aldoxorubicin may be safe, effective for advanced soft-tissue sarcoma
Single-agent aldoxorubicinshowed superior efficacy over doxorubicin and manageable adverse effects in advanced soft-tissue sarcoma.
Standard therapy for advanced soft-tissue sarcoma has not changed substantially in decades, and patient prognosis remains poor. Aldoxorubicin, a novel albumin-binding prodrug of doxorubicin, showed clinical activity against advanced soft-tissue sarcoma in phase 1 studies. Objective To evaluate efficacy and safety of aldoxorubicin vs doxorubicin in patients with advanced soft-tissue sarcoma.
READ FULL ARTICLE From oncology.jamanetwork.com
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs